Internal Medicine, Hematology & Oncology · Reno, NV
NPI
1881906121
Since 2010
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
5423 Reno Corporate Dr.
Reno, NV, 89511
Phone (775) 329-0873
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.2M
163,463 services
Medicare patients, 2024
759
Average age 75
Drug cost, 2024
$6.7M
1,502 prescriptions
Company payments, 2025
$793
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Juan A Cattoni III was code J9263 (injection, oxaliplatin, 0.5 mg), 16,976 times for 18 patients. In total Juan A Cattoni III billed 163,463 services in 153 codes, and Medicare paid $3.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-05-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 16,976 | 18 | $0.06 | $951 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 16,200 | 34 | $44.81 | $726K |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 9,750 | 13 | $0.87 | $8,513 |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 9,360 | 21 | $39.22 | $367K |
| J0185 Injection, aprepitant, 1 mg | Office | 5,850 | 17 | $1.33 | $7,810 |
| J9267 Injection, paclitaxel, 1 mg | Office | 4,103 | 18 | $0.08 | $324 |
| J0897 Injection, denosumab, 1 mg | Office | 2,640 | 21 | $20.52 | $54K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,277 | 97 | $0.09 | $202 |
| J0894 Injection, decitabine, 1 mg | Office | 1,900 | 13 | $1.24 | $2,358 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,880 | 85 | $0.69 | $1,289 |
| Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 1,390 | 12 | $16.29 | $23K |
| 99214 Office E&M - Established | Office | 1,170 | 466 | $93.43 | $109K |
| 85025 Blood Count | Office | 984 | 461 | $7.58 | $7,457 |
| 36415 Venipuncture Blood Collection | Office | 877 | 427 | $8.59 | $7,536 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 764 | 27 | $0.07 | $54.76 |
By year: 2022 $2.2M for 106,149 services; 2023 $2.8M for 137,325 services; 2024 $3.2M for 163,463 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 984 | 461 | $7.58 | $7,457 |
| 36415 Venipuncture Blood Collection | 877 | 427 | $8.59 | $7,536 |
| 80053 Clinical Chemistry | 589 | 329 | $10.31 | $6,072 |
| 83615 Clinical Chemistry | 112 | 73 | $5.84 | $654 |
| 82728 Clinical Chemistry | 53 | 44 | $13.36 | $708 |
| 84443 Clinical Chemistry | 49 | 34 | $16.46 | $807 |
| 83550 Clinical Chemistry | 46 | 39 | $8.57 | $394 |
| 83540 Clinical Chemistry | 42 | 37 | $6.19 | $260 |
| 83735 Clinical Chemistry | 40 | 38 | $6.57 | $263 |
| 84550 Clinical Chemistry | 35 | 23 | $4.33 | $152 |
Medicare prescription drug claims, 2024
In 2024, the drug Juan A Cattoni III prescribed most often to Medicare patients was Anastrozole, with 121 prescriptions and refills. In total Juan A Cattoni III wrote 1,502 Medicare prescriptions that cost $6.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 121 | 302 | 35 | $3,176 |
| Alendronate Sodium Generic | 102 | 230 | 25 | $988 |
| Hydroxyurea Generic | 99 | 231 | 25 | $3,539 |
| Eliquis Apixaban | 66 | 91 | 18 | $54K |
| Lenalidomide Generic | 63 | 63 | Under 11 | $774K |
| Prednisone Generic | 61 | 61 | 15 | $334 |
| Abiraterone Acetate Generic | 53 | 53 | Under 11 | $82K |
| Acyclovir Generic | 51 | 91 | 13 | $961 |
| Revlimid Lenalidomide | 44 | 44 | Under 11 | $677K |
| Imbruvica Ibrutinib | 43 | 43 | Under 11 | $688K |
| Gabapentin Generic | 40 | 48 | Under 11 | $441 |
| Levothyroxine Sodium Generic | 33 | 57 | 11 | $252 |
| Jakafi Ruxolitinib Phosphate | 30 | 30 | Under 11 | $507K |
| Tagrisso Osimertinib Mesylate | 27 | 27 | Under 11 | $430K |
| Dexamethasone Generic | 22 | 22 | Under 11 | $501 |
Brand drugs: 471 claims; generic drugs: 1,031 claims; opioid claims: 30.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Juan A Cattoni III $793 ($793 in general payments such as food, travel and fees) from 21 companies. The largest payer was E.R. Squibb & Sons, L.L.C. with $167.
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. BMY | 6 | $167 |
| Astellas Pharma US Inc 4503.T | 3 | $68.23 |
| Genzyme Corporation SNY | 2 | $62.93 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $55.58 |
| Exelixis Inc. EXEL | 2 | $48.69 |
| Pfizer Inc. PFE | 2 | $42.34 |
| Deciphera Pharmaceuticals Inc. | 1 | $33.53 |
| SpringWorks Therapeutics, Inc. | 1 | $31.52 |
| Array Biopharma Inc PFE | 1 | $30.17 |
| TerSera Therapeutics LLC | 1 | $29.8 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.